Cytocast Information

MECHANISTIC DRUG SAFETY INTELLIGENCE PLATFORM Cytocast is a TechBio company developing the CYTOCAST DIGITAL TWIN Platform™ for mechanistic drug safety prediction. We help pharmaceutical teams identify and understand side-effect risks early—before costly late-stage failure—by modeling how compounds perturb targets, pathways, and human tissues. INDUSTRY CONTEXT The pharmaceutical industry is transitioning from empirical safety assessment toward mechanistic, model-based approaches. Cytocast is part of this shift—enabling earlier, more predictive safety evaluation aligned with emerging new directions. SCIENCE The CYTOCAST DIGITAL TWIN Platform™ integrates systems biology, artificial intelligence, and molecular simulation to model how drugs perturb biological systems and lead to clinical side effects. Our platform connects: compound → targets & off-targets → perturbed pathways → clinical side effects, enabling earlier, more informed decisions in drug discovery. WHAT MAKES CYTOCAST DIFFERENT • Mechanistic, not black-box predictions • System-level modeling • Human-relevant safety insight beyond toxicity proxies • Clinically interpretable outputs for decision-making • Safety-first approach, complementing efficacy-driven discovery USE CASES • Early safety risk screening in drug discovery • Lead vs backup compound selection • Mechanistic investigation of adverse effects • Portfolio-level safety comparison and prioritization VISION We believe drug safety should be predictable, not reactive. Our vision is to make mechanistic, human-relevant safety model TEAM Our team combines expertise in systems biology, computational biology, high-performance computing, and drug discovery—bridging scientific rigor with scalable technology. GET IN TOUCH 📬 Contact us if you: • want to evaluate early safety risk in your pipeline • are exploring model-informed drug development approaches • are interested in collaboration or partnership